Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Propiram. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A known ✓ | Q03164 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propiram SCHEMBL11079155 | 1.00 | MEN1 (0.48) | MEN1KMT2AHTR1AACHEOPRM1 | |
| Propiram SCHEMBL592478 | 1.00 | MEN1 (0.48) | MEN1KMT2AHTR1AACHEOPRM1 | |
| Propiram SCHEMBL38655379 | 0.94 | MEN1 (0.52) | MEN1KMT2AHTR1AACHEOPRM1 | |
| Propiram SCHEMBL26193 | 0.94 | MEN1 (0.52) | MEN1KMT2AHTR1AACHEOPRM1 | |
| Propiram SCHEMBL3093165 | 0.92 | MEN1 (0.52) | MEN1KMT2AHTR1AACHEOPRM1 | |
| SCHEMBL26930970 | 0.80 | OPRM1 (0.43) | MEN1KMT2AHTR1AOPRM1SIGMAR1 | |
| Phenampromide SCHEMBL907886 | 0.78 | OPRM1 (0.47) | MEN1KMT2AOPRM1SMN1; SMN2 | |
| Phenampromide SCHEMBL907884 | 0.78 | OPRM1 (0.47) | MEN1KMT2AOPRM1SMN1; SMN2 | |
| Phenampromide SCHEMBL11661873 | 0.77 | ALDH1A1 (0.49) | MEN1KMT2AOPRM1SMN1; SMN2 | |
| Phenampromide SCHEMBL11661877 | 0.77 | ALDH1A1 (0.49) | MEN1KMT2AOPRM1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152319-A1 | ORAL APPLIANCE FOR DELIVERY OF MEDICAMENTS AND/OR OTHER SUBSTANCES | Emanate Biomedical, Inc. (US) | 2025-05-15 | — | — | US | disclosed |
| US-12296085-B2 | Method for extracorporeal treatment of preeclampsia and related disorders | ImMutriX Therapeutics, Inc. (US) | 2025-05-13 | — | — | US | disclosed |
| US-20250049928-A1 | ANESTHETIC PRODRUGS AND DERIVATIVES THEREOF FOR PROLONGED SENSORY SELECTIVE NERVE BLOCKAGE | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA | 2025-02-13 | — | — | US | disclosed |
| US-20250032221-A1 | ORTHODONTIC DEVICES FOR DELIVERY OF AN ACTIVE AGENT | Smylio Inc. (US) | 2025-01-30 | — | — | US | disclosed |
| US-12207984-B2 | Oral appliance for delivery of medicaments and/or other substances | Emanate Biomedical, Inc. (US) | 2025-01-28 | — | — | US | disclosed |
| CN-118613231-A | Orthodontic device for delivering active agents | 斯米利奥公司 | 2024-09-06 | — | — | CN | disclosed |
| US-20240294909-A1 | AGENTS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF HYPOXIA AND ISCHEMIA-RELATED DISORDERS | MERAND PHARMACEUTICALS INC (US) | 2024-09-05 | — | — | US | disclosed |
| US-20240247313-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2024-07-25 | — | — | US | disclosed |
| CN-117280030-A | Agents, compositions and methods for treating hypoxia and ischemia related conditions | 梅兰德制药公司 | 2023-12-22 | — | — | CN | disclosed |
| EP-3423102-B1 | COMPOSITION FOR USE IN THE TREATMENT OF PREECLAMPSIA | IMMUTRIX THERAPEUTICS INC (US) | 2022-09-07 | — | — | EP | disclosed |
| WO-2022174113-A1 | AGENTS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF HYPOXIA AND ISCHEMIA-RELATED DISORDERS | MERAND PHARMACEUTICALS, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| US-20220220561-A1 | METHODS AND CLINICAL PROTOCOLS AND KITS PERTAINING TO MAKING AND USING THERAPEUTIC COMPOSITIONS FOR CELLULAR TREATMENT | Advanced ReGen Medical Technologies, LLC | 2022-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240247313-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | SLC6A4, SLC6A3, SLC6A2 | MEN1 4859/4885KMT2A 1923/4885HTR1A 16/4885 |
| US-20250049928-A1 | ANESTHETIC PRODRUGS AND DERIVATIVES THEREOF FOR PROLONGED SENSORY SELECTIVE NERVE BLOCKAGE | TRPV1, OPRL1, TRPA1 | MEN1 4804/4885KMT2A 3880/4885HTR1A 505/4885 |
| US-12296085-B2 | Method for extracorporeal treatment of preeclampsia and related disorders | TEK, FLT4, PGF | MEN1 1127/4885KMT2A 2469/4885HTR1A 4099/4885 |
| US-20220220561-A1 | METHODS AND CLINICAL PROTOCOLS AND KITS PERTAINING TO MAKING AND USING THERAPEUTIC COMPOSITIONS FOR CELLULAR TREATMENT | CD47, HAVCR2, BST2 | MEN1 2574/4885KMT2A 4472/4885HTR1A 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.